nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.0619	0.127	CbGbCtD
Epoprostenol—CYP2C9—Glipizide—type 2 diabetes mellitus	0.0566	0.116	CbGbCtD
Epoprostenol—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.0526	0.108	CbGbCtD
Epoprostenol—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.0447	0.0916	CbGbCtD
Epoprostenol—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.0447	0.0916	CbGbCtD
Epoprostenol—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.0413	0.0845	CbGbCtD
Epoprostenol—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.0399	0.0816	CbGbCtD
Epoprostenol—CYP2C9—Valsartan—type 2 diabetes mellitus	0.0365	0.0747	CbGbCtD
Epoprostenol—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.0339	0.0694	CbGbCtD
Epoprostenol—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.0325	0.0665	CbGbCtD
Epoprostenol—CYP2C9—Glyburide—type 2 diabetes mellitus	0.0229	0.0469	CbGbCtD
Epoprostenol—CYP2C9—Losartan—type 2 diabetes mellitus	0.021	0.0429	CbGbCtD
Epoprostenol—PTGIS—artery—type 2 diabetes mellitus	0.0106	0.151	CbGeAlD
Epoprostenol—P2RY12—artery—type 2 diabetes mellitus	0.00952	0.136	CbGeAlD
Epoprostenol—PTGIS—endothelium—type 2 diabetes mellitus	0.00893	0.128	CbGeAlD
Epoprostenol—PTGIR—artery—type 2 diabetes mellitus	0.00607	0.0868	CbGeAlD
Epoprostenol—PTGIR—endothelium—type 2 diabetes mellitus	0.00513	0.0733	CbGeAlD
Epoprostenol—PTGIS—cardiovascular system—type 2 diabetes mellitus	0.00367	0.0525	CbGeAlD
Epoprostenol—PTGER1—kidney—type 2 diabetes mellitus	0.00334	0.0478	CbGeAlD
Epoprostenol—PTGER1—pancreas—type 2 diabetes mellitus	0.00332	0.0474	CbGeAlD
Epoprostenol—P2RY12—cardiovascular system—type 2 diabetes mellitus	0.00331	0.0473	CbGeAlD
Epoprostenol—PTGIS—adipose tissue—type 2 diabetes mellitus	0.00324	0.0463	CbGeAlD
Epoprostenol—PTGIS—liver—type 2 diabetes mellitus	0.00227	0.0325	CbGeAlD
Epoprostenol—PTGIR—cardiovascular system—type 2 diabetes mellitus	0.00211	0.0302	CbGeAlD
Epoprostenol—PTGIR—kidney—type 2 diabetes mellitus	0.00206	0.0295	CbGeAlD
Epoprostenol—PTGIR—pancreas—type 2 diabetes mellitus	0.00205	0.0293	CbGeAlD
Epoprostenol—PTGIR—adipose tissue—type 2 diabetes mellitus	0.00186	0.0266	CbGeAlD
Epoprostenol—PTGIR—liver—type 2 diabetes mellitus	0.0013	0.0186	CbGeAlD
Epoprostenol—Dinoprostone—CYP11A1—type 2 diabetes mellitus	0.000842	0.731	CrCbGaD
Epoprostenol—CYP2C9—cardiovascular system—type 2 diabetes mellitus	0.000754	0.0108	CbGeAlD
Epoprostenol—CYP2C9—liver—type 2 diabetes mellitus	0.000466	0.00666	CbGeAlD
Epoprostenol—Dinoprostone—CYP1A2—type 2 diabetes mellitus	0.000309	0.268	CrCbGaD
Epoprostenol—Headache—Glimepiride—type 2 diabetes mellitus	0.000168	0.000663	CcSEcCtD
Epoprostenol—Cough—Irbesartan—type 2 diabetes mellitus	0.000168	0.000662	CcSEcCtD
Epoprostenol—Headache—Sitagliptin—type 2 diabetes mellitus	0.000167	0.000661	CcSEcCtD
Epoprostenol—Anaemia—Losartan—type 2 diabetes mellitus	0.000167	0.000659	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000166	0.000656	CcSEcCtD
Epoprostenol—Agitation—Losartan—type 2 diabetes mellitus	0.000166	0.000656	CcSEcCtD
Epoprostenol—Oedema—Metformin—type 2 diabetes mellitus	0.000166	0.000656	CcSEcCtD
Epoprostenol—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000166	0.000653	CcSEcCtD
Epoprostenol—Flushing—Ramipril—type 2 diabetes mellitus	0.000165	0.000652	CcSEcCtD
Epoprostenol—Infection—Metformin—type 2 diabetes mellitus	0.000165	0.000651	CcSEcCtD
Epoprostenol—Insomnia—Valsartan—type 2 diabetes mellitus	0.000165	0.000651	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000164	0.000648	CcSEcCtD
Epoprostenol—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000164	0.000647	CcSEcCtD
Epoprostenol—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000164	0.000645	CcSEcCtD
Epoprostenol—Myalgia—Irbesartan—type 2 diabetes mellitus	0.000164	0.000645	CcSEcCtD
Epoprostenol—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000164	0.000645	CcSEcCtD
Epoprostenol—Shock—Metformin—type 2 diabetes mellitus	0.000163	0.000645	CcSEcCtD
Epoprostenol—Insomnia—Orlistat—type 2 diabetes mellitus	0.000163	0.000644	CcSEcCtD
Epoprostenol—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000163	0.000643	CcSEcCtD
Epoprostenol—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000163	0.000643	CcSEcCtD
Epoprostenol—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000163	0.000643	CcSEcCtD
Epoprostenol—Thrombocytopenia—Metformin—type 2 diabetes mellitus	0.000163	0.000642	CcSEcCtD
Epoprostenol—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000163	0.000642	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000162	0.000641	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000162	0.000641	CcSEcCtD
Epoprostenol—Somnolence—Valsartan—type 2 diabetes mellitus	0.000162	0.00064	CcSEcCtD
Epoprostenol—Syncope—Losartan—type 2 diabetes mellitus	0.000162	0.00064	CcSEcCtD
Epoprostenol—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000162	0.000639	CcSEcCtD
Epoprostenol—Skin disorder—Metformin—type 2 diabetes mellitus	0.000161	0.000637	CcSEcCtD
Epoprostenol—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000161	0.000634	CcSEcCtD
Epoprostenol—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000161	0.000634	CcSEcCtD
Epoprostenol—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000161	0.000633	CcSEcCtD
Epoprostenol—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.00016	0.000631	CcSEcCtD
Epoprostenol—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.00016	0.000631	CcSEcCtD
Epoprostenol—Palpitations—Losartan—type 2 diabetes mellitus	0.00016	0.000631	CcSEcCtD
Epoprostenol—Nausea—Glimepiride—type 2 diabetes mellitus	0.000159	0.000629	CcSEcCtD
Epoprostenol—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000159	0.000627	CcSEcCtD
Epoprostenol—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000159	0.000627	CcSEcCtD
Epoprostenol—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000159	0.000626	CcSEcCtD
Epoprostenol—Asthenia—Glyburide—type 2 diabetes mellitus	0.000159	0.000626	CcSEcCtD
Epoprostenol—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000159	0.000626	CcSEcCtD
Epoprostenol—Anorexia—Metformin—type 2 diabetes mellitus	0.000158	0.000625	CcSEcCtD
Epoprostenol—Cough—Losartan—type 2 diabetes mellitus	0.000158	0.000623	CcSEcCtD
Epoprostenol—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000158	0.000623	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000158	0.000622	CcSEcCtD
Epoprostenol—Fatigue—Valsartan—type 2 diabetes mellitus	0.000157	0.000621	CcSEcCtD
Epoprostenol—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000157	0.00062	CcSEcCtD
Epoprostenol—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000157	0.00062	CcSEcCtD
Epoprostenol—Oedema—Irbesartan—type 2 diabetes mellitus	0.000157	0.000619	CcSEcCtD
Epoprostenol—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000157	0.000619	CcSEcCtD
Epoprostenol—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000157	0.000618	CcSEcCtD
Epoprostenol—Pruritus—Glyburide—type 2 diabetes mellitus	0.000156	0.000617	CcSEcCtD
Epoprostenol—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000156	0.000616	CcSEcCtD
Epoprostenol—Constipation—Valsartan—type 2 diabetes mellitus	0.000156	0.000616	CcSEcCtD
Epoprostenol—Infection—Irbesartan—type 2 diabetes mellitus	0.000156	0.000615	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000156	0.000614	CcSEcCtD
Epoprostenol—Fatigue—Orlistat—type 2 diabetes mellitus	0.000155	0.000613	CcSEcCtD
Epoprostenol—Hypotension—Metformin—type 2 diabetes mellitus	0.000155	0.000613	CcSEcCtD
Epoprostenol—Shock—Irbesartan—type 2 diabetes mellitus	0.000154	0.000609	CcSEcCtD
Epoprostenol—Pain—Orlistat—type 2 diabetes mellitus	0.000154	0.000608	CcSEcCtD
Epoprostenol—Arthralgia—Losartan—type 2 diabetes mellitus	0.000154	0.000607	CcSEcCtD
Epoprostenol—Myalgia—Losartan—type 2 diabetes mellitus	0.000154	0.000607	CcSEcCtD
Epoprostenol—Chest pain—Losartan—type 2 diabetes mellitus	0.000154	0.000607	CcSEcCtD
Epoprostenol—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000154	0.000607	CcSEcCtD
Epoprostenol—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000154	0.000607	CcSEcCtD
Epoprostenol—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	0.000154	0.000606	CcSEcCtD
Epoprostenol—Anxiety—Losartan—type 2 diabetes mellitus	0.000153	0.000605	CcSEcCtD
Epoprostenol—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000153	0.000604	CcSEcCtD
Epoprostenol—Rash—Bromocriptine—type 2 diabetes mellitus	0.000153	0.000602	CcSEcCtD
Epoprostenol—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000152	0.000601	CcSEcCtD
Epoprostenol—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000152	0.000601	CcSEcCtD
Epoprostenol—Tension—Ramipril—type 2 diabetes mellitus	0.000152	0.0006	CcSEcCtD
Epoprostenol—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000152	0.000598	CcSEcCtD
Epoprostenol—Headache—Bromocriptine—type 2 diabetes mellitus	0.000152	0.000598	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000151	0.000597	CcSEcCtD
Epoprostenol—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000151	0.000597	CcSEcCtD
Epoprostenol—Nervousness—Ramipril—type 2 diabetes mellitus	0.000151	0.000594	CcSEcCtD
Epoprostenol—Dry mouth—Losartan—type 2 diabetes mellitus	0.000151	0.000594	CcSEcCtD
Epoprostenol—Anorexia—Irbesartan—type 2 diabetes mellitus	0.000149	0.00059	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000149	0.000589	CcSEcCtD
Epoprostenol—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000149	0.000589	CcSEcCtD
Epoprostenol—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000149	0.000588	CcSEcCtD
Epoprostenol—Confusional state—Losartan—type 2 diabetes mellitus	0.000149	0.000587	CcSEcCtD
Epoprostenol—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000148	0.000585	CcSEcCtD
Epoprostenol—Somnolence—Metformin—type 2 diabetes mellitus	0.000148	0.000583	CcSEcCtD
Epoprostenol—Oedema—Losartan—type 2 diabetes mellitus	0.000148	0.000582	CcSEcCtD
Epoprostenol—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000148	0.000582	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000147	0.000582	CcSEcCtD
Epoprostenol—Infection—Losartan—type 2 diabetes mellitus	0.000147	0.000579	CcSEcCtD
Epoprostenol—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000147	0.000578	CcSEcCtD
Epoprostenol—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000146	0.000577	CcSEcCtD
Epoprostenol—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000146	0.000577	CcSEcCtD
Epoprostenol—Tremor—Ramipril—type 2 diabetes mellitus	0.000145	0.000573	CcSEcCtD
Epoprostenol—Shock—Losartan—type 2 diabetes mellitus	0.000145	0.000573	CcSEcCtD
Epoprostenol—Urticaria—Valsartan—type 2 diabetes mellitus	0.000145	0.000572	CcSEcCtD
Epoprostenol—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000145	0.000571	CcSEcCtD
Epoprostenol—Thrombocytopenia—Losartan—type 2 diabetes mellitus	0.000144	0.00057	CcSEcCtD
Epoprostenol—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000144	0.00057	CcSEcCtD
Epoprostenol—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000144	0.000569	CcSEcCtD
Epoprostenol—Tachycardia—Losartan—type 2 diabetes mellitus	0.000144	0.000568	CcSEcCtD
Epoprostenol—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000144	0.000567	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000143	0.000566	CcSEcCtD
Epoprostenol—Fatigue—Metformin—type 2 diabetes mellitus	0.000143	0.000565	CcSEcCtD
Epoprostenol—Urticaria—Orlistat—type 2 diabetes mellitus	0.000143	0.000565	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000143	0.000564	CcSEcCtD
Epoprostenol—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000143	0.000563	CcSEcCtD
Epoprostenol—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000143	0.000562	CcSEcCtD
Epoprostenol—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000143	0.000562	CcSEcCtD
Epoprostenol—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000142	0.000562	CcSEcCtD
Epoprostenol—Agitation—Ramipril—type 2 diabetes mellitus	0.000142	0.000562	CcSEcCtD
Epoprostenol—Constipation—Metformin—type 2 diabetes mellitus	0.000142	0.000561	CcSEcCtD
Epoprostenol—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000141	0.000556	CcSEcCtD
Epoprostenol—Anorexia—Losartan—type 2 diabetes mellitus	0.000141	0.000555	CcSEcCtD
Epoprostenol—Vomiting—Glyburide—type 2 diabetes mellitus	0.000141	0.000555	CcSEcCtD
Epoprostenol—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000141	0.000554	CcSEcCtD
Epoprostenol—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.00014	0.000552	CcSEcCtD
Epoprostenol—Rash—Glyburide—type 2 diabetes mellitus	0.000139	0.00055	CcSEcCtD
Epoprostenol—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000139	0.00055	CcSEcCtD
Epoprostenol—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000139	0.00055	CcSEcCtD
Epoprostenol—Syncope—Ramipril—type 2 diabetes mellitus	0.000139	0.000549	CcSEcCtD
Epoprostenol—Headache—Glyburide—type 2 diabetes mellitus	0.000139	0.000547	CcSEcCtD
Epoprostenol—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000138	0.000545	CcSEcCtD
Epoprostenol—Hypotension—Losartan—type 2 diabetes mellitus	0.000138	0.000544	CcSEcCtD
Epoprostenol—Palpitations—Ramipril—type 2 diabetes mellitus	0.000137	0.000541	CcSEcCtD
Epoprostenol—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000136	0.000538	CcSEcCtD
Epoprostenol—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000136	0.000538	CcSEcCtD
Epoprostenol—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000136	0.000536	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000136	0.000536	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000135	0.000534	CcSEcCtD
Epoprostenol—Cough—Ramipril—type 2 diabetes mellitus	0.000135	0.000534	CcSEcCtD
Epoprostenol—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000135	0.000533	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000134	0.000531	CcSEcCtD
Epoprostenol—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000134	0.00053	CcSEcCtD
Epoprostenol—Pain—Irbesartan—type 2 diabetes mellitus	0.000134	0.000529	CcSEcCtD
Epoprostenol—Constipation—Irbesartan—type 2 diabetes mellitus	0.000134	0.000529	CcSEcCtD
Epoprostenol—Insomnia—Losartan—type 2 diabetes mellitus	0.000133	0.000527	CcSEcCtD
Epoprostenol—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000133	0.000524	CcSEcCtD
Epoprostenol—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000133	0.000523	CcSEcCtD
Epoprostenol—Urticaria—Metformin—type 2 diabetes mellitus	0.000132	0.000521	CcSEcCtD
Epoprostenol—Myalgia—Ramipril—type 2 diabetes mellitus	0.000132	0.000521	CcSEcCtD
Epoprostenol—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000132	0.000521	CcSEcCtD
Epoprostenol—Chest pain—Ramipril—type 2 diabetes mellitus	0.000132	0.000521	CcSEcCtD
Epoprostenol—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000132	0.000519	CcSEcCtD
Epoprostenol—Anxiety—Ramipril—type 2 diabetes mellitus	0.000132	0.000519	CcSEcCtD
Epoprostenol—Nausea—Glyburide—type 2 diabetes mellitus	0.000131	0.000518	CcSEcCtD
Epoprostenol—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000131	0.000518	CcSEcCtD
Epoprostenol—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000131	0.000518	CcSEcCtD
Epoprostenol—Somnolence—Losartan—type 2 diabetes mellitus	0.000131	0.000518	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000131	0.000517	CcSEcCtD
Epoprostenol—Asthenia—Valsartan—type 2 diabetes mellitus	0.000131	0.000517	CcSEcCtD
Epoprostenol—Dyspepsia—Losartan—type 2 diabetes mellitus	0.00013	0.000513	CcSEcCtD
Epoprostenol—Asthenia—Orlistat—type 2 diabetes mellitus	0.000129	0.00051	CcSEcCtD
Epoprostenol—Pruritus—Valsartan—type 2 diabetes mellitus	0.000129	0.000509	CcSEcCtD
Epoprostenol—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000129	0.000509	CcSEcCtD
Epoprostenol—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000128	0.000506	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000128	0.000506	CcSEcCtD
Epoprostenol—Confusional state—Ramipril—type 2 diabetes mellitus	0.000128	0.000503	CcSEcCtD
Epoprostenol—Pruritus—Orlistat—type 2 diabetes mellitus	0.000128	0.000503	CcSEcCtD
Epoprostenol—Fatigue—Losartan—type 2 diabetes mellitus	0.000127	0.000502	CcSEcCtD
Epoprostenol—Oedema—Ramipril—type 2 diabetes mellitus	0.000127	0.000499	CcSEcCtD
Epoprostenol—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000127	0.000499	CcSEcCtD
Epoprostenol—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000126	0.000498	CcSEcCtD
Epoprostenol—Constipation—Losartan—type 2 diabetes mellitus	0.000126	0.000498	CcSEcCtD
Epoprostenol—Pain—Losartan—type 2 diabetes mellitus	0.000126	0.000498	CcSEcCtD
Epoprostenol—Rash—Gliclazide—type 2 diabetes mellitus	0.000125	0.000494	CcSEcCtD
Epoprostenol—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000125	0.000494	CcSEcCtD
Epoprostenol—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000125	0.000493	CcSEcCtD
Epoprostenol—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000125	0.000492	CcSEcCtD
Epoprostenol—Shock—Ramipril—type 2 diabetes mellitus	0.000124	0.000491	CcSEcCtD
Epoprostenol—Headache—Gliclazide—type 2 diabetes mellitus	0.000124	0.000491	CcSEcCtD
Epoprostenol—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000124	0.00049	CcSEcCtD
Epoprostenol—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000124	0.000489	CcSEcCtD
Epoprostenol—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000124	0.000489	CcSEcCtD
Epoprostenol—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	0.000124	0.000489	CcSEcCtD
Epoprostenol—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000123	0.000487	CcSEcCtD
Epoprostenol—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000123	0.000487	CcSEcCtD
Epoprostenol—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000123	0.000485	CcSEcCtD
Epoprostenol—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000122	0.000483	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000121	0.000476	CcSEcCtD
Epoprostenol—Dizziness—Valsartan—type 2 diabetes mellitus	0.000121	0.000476	CcSEcCtD
Epoprostenol—Anorexia—Ramipril—type 2 diabetes mellitus	0.000121	0.000476	CcSEcCtD
Epoprostenol—Dizziness—Orlistat—type 2 diabetes mellitus	0.000119	0.00047	CcSEcCtD
Epoprostenol—Asthenia—Metformin—type 2 diabetes mellitus	0.000119	0.00047	CcSEcCtD
Epoprostenol—Hypotension—Ramipril—type 2 diabetes mellitus	0.000118	0.000467	CcSEcCtD
Epoprostenol—Nausea—Gliclazide—type 2 diabetes mellitus	0.000118	0.000466	CcSEcCtD
Epoprostenol—Pruritus—Metformin—type 2 diabetes mellitus	0.000118	0.000464	CcSEcCtD
Epoprostenol—Urticaria—Losartan—type 2 diabetes mellitus	0.000117	0.000463	CcSEcCtD
Epoprostenol—Body temperature increased—Losartan—type 2 diabetes mellitus	0.000117	0.00046	CcSEcCtD
Epoprostenol—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000117	0.00046	CcSEcCtD
Epoprostenol—Vomiting—Valsartan—type 2 diabetes mellitus	0.000116	0.000458	CcSEcCtD
Epoprostenol—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000116	0.000456	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000115	0.000455	CcSEcCtD
Epoprostenol—Rash—Valsartan—type 2 diabetes mellitus	0.000115	0.000454	CcSEcCtD
Epoprostenol—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000115	0.000454	CcSEcCtD
Epoprostenol—Vomiting—Orlistat—type 2 diabetes mellitus	0.000115	0.000452	CcSEcCtD
Epoprostenol—Insomnia—Ramipril—type 2 diabetes mellitus	0.000114	0.000452	CcSEcCtD
Epoprostenol—Headache—Valsartan—type 2 diabetes mellitus	0.000114	0.000451	CcSEcCtD
Epoprostenol—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000114	0.000449	CcSEcCtD
Epoprostenol—Rash—Orlistat—type 2 diabetes mellitus	0.000114	0.000449	CcSEcCtD
Epoprostenol—Paraesthesia—Ramipril—type 2 diabetes mellitus	0.000114	0.000448	CcSEcCtD
Epoprostenol—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000114	0.000448	CcSEcCtD
Epoprostenol—Headache—Orlistat—type 2 diabetes mellitus	0.000113	0.000446	CcSEcCtD
Epoprostenol—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000113	0.000445	CcSEcCtD
Epoprostenol—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000113	0.000444	CcSEcCtD
Epoprostenol—Somnolence—Ramipril—type 2 diabetes mellitus	0.000112	0.000444	CcSEcCtD
Epoprostenol—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000111	0.00044	CcSEcCtD
Epoprostenol—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000111	0.000438	CcSEcCtD
Epoprostenol—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.00011	0.000434	CcSEcCtD
Epoprostenol—Dizziness—Metformin—type 2 diabetes mellitus	0.00011	0.000434	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000109	0.000431	CcSEcCtD
Epoprostenol—Fatigue—Ramipril—type 2 diabetes mellitus	0.000109	0.00043	CcSEcCtD
Epoprostenol—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000109	0.000429	CcSEcCtD
Epoprostenol—Nausea—Valsartan—type 2 diabetes mellitus	0.000108	0.000428	CcSEcCtD
Epoprostenol—Constipation—Ramipril—type 2 diabetes mellitus	0.000108	0.000427	CcSEcCtD
Epoprostenol—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000107	0.000423	CcSEcCtD
Epoprostenol—Nausea—Orlistat—type 2 diabetes mellitus	0.000107	0.000423	CcSEcCtD
Epoprostenol—Asthenia—Losartan—type 2 diabetes mellitus	0.000106	0.000418	CcSEcCtD
Epoprostenol—Vomiting—Metformin—type 2 diabetes mellitus	0.000106	0.000417	CcSEcCtD
Epoprostenol—Rash—Metformin—type 2 diabetes mellitus	0.000105	0.000413	CcSEcCtD
Epoprostenol—Dermatitis—Metformin—type 2 diabetes mellitus	0.000105	0.000413	CcSEcCtD
Epoprostenol—Pruritus—Losartan—type 2 diabetes mellitus	0.000104	0.000412	CcSEcCtD
Epoprostenol—Headache—Metformin—type 2 diabetes mellitus	0.000104	0.000411	CcSEcCtD
Epoprostenol—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000104	0.000409	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000103	0.000408	CcSEcCtD
Epoprostenol—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000101	0.000398	CcSEcCtD
Epoprostenol—Urticaria—Ramipril—type 2 diabetes mellitus	0.000101	0.000397	CcSEcCtD
Epoprostenol—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.0001	0.000395	CcSEcCtD
Epoprostenol—Body temperature increased—Ramipril—type 2 diabetes mellitus	0.0001	0.000395	CcSEcCtD
Epoprostenol—Vomiting—Irbesartan—type 2 diabetes mellitus	9.97e-05	0.000393	CcSEcCtD
Epoprostenol—Rash—Irbesartan—type 2 diabetes mellitus	9.89e-05	0.00039	CcSEcCtD
Epoprostenol—Dermatitis—Irbesartan—type 2 diabetes mellitus	9.88e-05	0.00039	CcSEcCtD
Epoprostenol—Nausea—Metformin—type 2 diabetes mellitus	9.87e-05	0.000389	CcSEcCtD
Epoprostenol—Headache—Irbesartan—type 2 diabetes mellitus	9.82e-05	0.000388	CcSEcCtD
Epoprostenol—Dizziness—Losartan—type 2 diabetes mellitus	9.76e-05	0.000385	CcSEcCtD
Epoprostenol—Vomiting—Losartan—type 2 diabetes mellitus	9.38e-05	0.00037	CcSEcCtD
Epoprostenol—Hypersensitivity—Ramipril—type 2 diabetes mellitus	9.32e-05	0.000368	CcSEcCtD
Epoprostenol—Nausea—Irbesartan—type 2 diabetes mellitus	9.31e-05	0.000368	CcSEcCtD
Epoprostenol—Rash—Losartan—type 2 diabetes mellitus	9.3e-05	0.000367	CcSEcCtD
Epoprostenol—Dermatitis—Losartan—type 2 diabetes mellitus	9.3e-05	0.000367	CcSEcCtD
Epoprostenol—Headache—Losartan—type 2 diabetes mellitus	9.24e-05	0.000365	CcSEcCtD
Epoprostenol—Asthenia—Ramipril—type 2 diabetes mellitus	9.08e-05	0.000358	CcSEcCtD
Epoprostenol—Pruritus—Ramipril—type 2 diabetes mellitus	8.95e-05	0.000353	CcSEcCtD
Epoprostenol—Nausea—Losartan—type 2 diabetes mellitus	8.77e-05	0.000346	CcSEcCtD
Epoprostenol—Diarrhoea—Ramipril—type 2 diabetes mellitus	8.66e-05	0.000342	CcSEcCtD
Epoprostenol—Dizziness—Ramipril—type 2 diabetes mellitus	8.37e-05	0.00033	CcSEcCtD
Epoprostenol—Vomiting—Ramipril—type 2 diabetes mellitus	8.05e-05	0.000317	CcSEcCtD
Epoprostenol—Rash—Ramipril—type 2 diabetes mellitus	7.98e-05	0.000315	CcSEcCtD
Epoprostenol—Dermatitis—Ramipril—type 2 diabetes mellitus	7.97e-05	0.000315	CcSEcCtD
Epoprostenol—Headache—Ramipril—type 2 diabetes mellitus	7.93e-05	0.000313	CcSEcCtD
Epoprostenol—Nausea—Ramipril—type 2 diabetes mellitus	7.52e-05	0.000297	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—AKT2—type 2 diabetes mellitus	2.4e-05	0.000129	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	2.4e-05	0.000129	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	2.4e-05	0.000129	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	2.4e-05	0.000129	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—INS—type 2 diabetes mellitus	2.4e-05	0.000128	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	2.4e-05	0.000128	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	2.37e-05	0.000127	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APOB—type 2 diabetes mellitus	2.34e-05	0.000125	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF1R—type 2 diabetes mellitus	2.33e-05	0.000124	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTGS2—type 2 diabetes mellitus	2.3e-05	0.000123	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EDN1—type 2 diabetes mellitus	2.3e-05	0.000123	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	2.28e-05	0.000122	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	2.28e-05	0.000122	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GNB3—type 2 diabetes mellitus	2.25e-05	0.000121	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GNB3—type 2 diabetes mellitus	2.25e-05	0.000121	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—LPL—type 2 diabetes mellitus	2.23e-05	0.000119	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP3—type 2 diabetes mellitus	2.22e-05	0.000119	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AVP—type 2 diabetes mellitus	2.22e-05	0.000119	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AVP—type 2 diabetes mellitus	2.22e-05	0.000119	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP3—type 2 diabetes mellitus	2.22e-05	0.000119	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF2—type 2 diabetes mellitus	2.21e-05	0.000118	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF2—type 2 diabetes mellitus	2.21e-05	0.000118	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	2.2e-05	0.000118	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	2.2e-05	0.000118	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ALB—type 2 diabetes mellitus	2.2e-05	0.000118	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.18e-05	0.000117	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	2.18e-05	0.000117	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	2.18e-05	0.000117	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AANAT—type 2 diabetes mellitus	2.15e-05	0.000115	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGDS—type 2 diabetes mellitus	2.15e-05	0.000115	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APOB—type 2 diabetes mellitus	2.15e-05	0.000115	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APOB—type 2 diabetes mellitus	2.15e-05	0.000115	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF1R—type 2 diabetes mellitus	2.14e-05	0.000115	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	2.14e-05	0.000115	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EDN1—type 2 diabetes mellitus	2.12e-05	0.000113	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EDN1—type 2 diabetes mellitus	2.12e-05	0.000113	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—NOS3—type 2 diabetes mellitus	2.11e-05	0.000113	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3R1—type 2 diabetes mellitus	2.11e-05	0.000113	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.09e-05	0.000112	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.05e-05	0.00011	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—LPL—type 2 diabetes mellitus	2.05e-05	0.00011	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—LPL—type 2 diabetes mellitus	2.05e-05	0.00011	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CPT1A—type 2 diabetes mellitus	2.05e-05	0.000109	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CDO1—type 2 diabetes mellitus	2.04e-05	0.000109	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPD2—type 2 diabetes mellitus	2.04e-05	0.000109	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.01e-05	0.000108	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.01e-05	0.000108	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—C3—type 2 diabetes mellitus	2.01e-05	0.000107	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—type 2 diabetes mellitus	1.99e-05	0.000107	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—type 2 diabetes mellitus	1.98e-05	0.000106	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AK1—type 2 diabetes mellitus	1.95e-05	0.000104	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—type 2 diabetes mellitus	1.93e-05	0.000103	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.93e-05	0.000103	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.93e-05	0.000103	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CETP—type 2 diabetes mellitus	1.92e-05	0.000103	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.92e-05	0.000102	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.91e-05	0.000102	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AGT—type 2 diabetes mellitus	1.91e-05	0.000102	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—AKT1—type 2 diabetes mellitus	1.9e-05	0.000102	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.89e-05	0.000101	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.89e-05	0.000101	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.88e-05	0.0001	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—LEP—type 2 diabetes mellitus	1.87e-05	0.0001	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APOE—type 2 diabetes mellitus	1.87e-05	0.0001	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SRC—type 2 diabetes mellitus	1.86e-05	9.95e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—C3—type 2 diabetes mellitus	1.85e-05	9.89e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.85e-05	9.89e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—C3—type 2 diabetes mellitus	1.85e-05	9.89e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC5A4—type 2 diabetes mellitus	1.8e-05	9.61e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MAT1A—type 2 diabetes mellitus	1.8e-05	9.61e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—SREBF1—type 2 diabetes mellitus	1.79e-05	9.57e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.76e-05	9.43e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.76e-05	9.43e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.76e-05	9.43e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.76e-05	9.41e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.76e-05	9.41e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AGT—type 2 diabetes mellitus	1.76e-05	9.39e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AGT—type 2 diabetes mellitus	1.76e-05	9.39e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—type 2 diabetes mellitus	1.76e-05	9.39e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—AKT1—type 2 diabetes mellitus	1.75e-05	9.35e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—HMGCR—type 2 diabetes mellitus	1.74e-05	9.31e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—G6PC—type 2 diabetes mellitus	1.73e-05	9.28e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ENPP1—type 2 diabetes mellitus	1.73e-05	9.28e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPP1R3C—type 2 diabetes mellitus	1.73e-05	9.28e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HBA2—type 2 diabetes mellitus	1.73e-05	9.28e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ND1—type 2 diabetes mellitus	1.73e-05	9.28e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.73e-05	9.24e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.73e-05	9.24e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APOE—type 2 diabetes mellitus	1.72e-05	9.21e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APOE—type 2 diabetes mellitus	1.72e-05	9.21e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—LEP—type 2 diabetes mellitus	1.72e-05	9.21e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—LEP—type 2 diabetes mellitus	1.72e-05	9.21e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.7e-05	9.1e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.7e-05	9.1e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GCGR—type 2 diabetes mellitus	1.68e-05	8.99e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.67e-05	8.92e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TGFB1—type 2 diabetes mellitus	1.66e-05	8.9e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EGFR—type 2 diabetes mellitus	1.63e-05	8.72e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.62e-05	8.68e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.62e-05	8.68e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—type 2 diabetes mellitus	1.62e-05	8.65e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—INS—type 2 diabetes mellitus	1.6e-05	8.54e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—OXCT1—type 2 diabetes mellitus	1.59e-05	8.49e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYTB—type 2 diabetes mellitus	1.59e-05	8.49e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.57e-05	8.41e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SRD5A1—type 2 diabetes mellitus	1.55e-05	8.27e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.54e-05	8.27e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.54e-05	8.26e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.54e-05	8.22e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.53e-05	8.21e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.53e-05	8.21e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HSD17B3—type 2 diabetes mellitus	1.47e-05	7.89e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—STAR—type 2 diabetes mellitus	1.47e-05	7.89e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ACACA—type 2 diabetes mellitus	1.47e-05	7.89e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—INS—type 2 diabetes mellitus	1.47e-05	7.86e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—INS—type 2 diabetes mellitus	1.47e-05	7.86e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.47e-05	7.85e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.45e-05	7.74e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.45e-05	7.74e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.42e-05	7.61e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.42e-05	7.61e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.42e-05	7.6e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.42e-05	7.6e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.41e-05	7.57e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.41e-05	7.57e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCC8—type 2 diabetes mellitus	1.41e-05	7.57e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CBS—type 2 diabetes mellitus	1.41e-05	7.57e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.4e-05	7.49e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.4e-05	7.49e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—COX2—type 2 diabetes mellitus	1.36e-05	7.28e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC5A2—type 2 diabetes mellitus	1.36e-05	7.28e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.35e-05	7.22e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.35e-05	7.22e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NCOA6—type 2 diabetes mellitus	1.34e-05	7.15e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARGC1A—type 2 diabetes mellitus	1.34e-05	7.15e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RELA—type 2 diabetes mellitus	1.32e-05	7.05e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—UCP2—type 2 diabetes mellitus	1.31e-05	7.03e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—UCP3—type 2 diabetes mellitus	1.31e-05	7.03e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HSD11B1—type 2 diabetes mellitus	1.31e-05	7.03e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.29e-05	6.9e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.29e-05	6.9e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.29e-05	6.9e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.29e-05	6.9e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOB—type 2 diabetes mellitus	1.27e-05	6.82e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—type 2 diabetes mellitus	1.25e-05	6.7e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PCK1—type 2 diabetes mellitus	1.24e-05	6.61e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—LPL—type 2 diabetes mellitus	1.22e-05	6.51e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.21e-05	6.49e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RELA—type 2 diabetes mellitus	1.21e-05	6.49e-05	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.2e-05	6.42e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.19e-05	6.36e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—type 2 diabetes mellitus	1.19e-05	6.35e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.18e-05	6.32e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HK1—type 2 diabetes mellitus	1.16e-05	6.19e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CD36—type 2 diabetes mellitus	1.16e-05	6.19e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—type 2 diabetes mellitus	1.16e-05	6.18e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.12e-05	6.01e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HSD3B2—type 2 diabetes mellitus	1.12e-05	5.98e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—KCNJ11—type 2 diabetes mellitus	1.12e-05	5.98e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GCKR—type 2 diabetes mellitus	1.12e-05	5.98e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LPA—type 2 diabetes mellitus	1.12e-05	5.98e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.11e-05	5.95e-05	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.1e-05	5.91e-05	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.1e-05	5.91e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.09e-05	5.85e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.09e-05	5.85e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.09e-05	5.83e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.09e-05	5.82e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.09e-05	5.82e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—type 2 diabetes mellitus	1.07e-05	5.75e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALDOB—type 2 diabetes mellitus	1.07e-05	5.73e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—AGT—type 2 diabetes mellitus	1.04e-05	5.57e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SRC—type 2 diabetes mellitus	1.04e-05	5.54e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.03e-05	5.53e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.03e-05	5.53e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.02e-05	5.47e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.02e-05	5.47e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	1.02e-05	5.46e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.01e-05	5.4e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	1.01e-05	5.39e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1e-05	5.37e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1e-05	5.37e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GLP1R—type 2 diabetes mellitus	9.96e-06	5.33e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—type 2 diabetes mellitus	9.68e-06	5.18e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SRC—type 2 diabetes mellitus	9.53e-06	5.1e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SRC—type 2 diabetes mellitus	9.53e-06	5.1e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC2A2—type 2 diabetes mellitus	9.3e-06	4.98e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.29e-06	4.97e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.29e-06	4.97e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.26e-06	4.95e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CPT1A—type 2 diabetes mellitus	9.11e-06	4.88e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTR—type 2 diabetes mellitus	9.11e-06	4.88e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.08e-06	4.86e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NAMPT—type 2 diabetes mellitus	8.94e-06	4.78e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	8.88e-06	4.75e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LIPC—type 2 diabetes mellitus	8.88e-06	4.75e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HBA1—type 2 diabetes mellitus	8.88e-06	4.75e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GCK—type 2 diabetes mellitus	8.88e-06	4.75e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP11A1—type 2 diabetes mellitus	8.83e-06	4.72e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC9A1—type 2 diabetes mellitus	8.67e-06	4.64e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CETP—type 2 diabetes mellitus	8.57e-06	4.58e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.52e-06	4.56e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.52e-06	4.56e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.36e-06	4.47e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.36e-06	4.47e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	7.99e-06	4.27e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SNAP25—type 2 diabetes mellitus	7.97e-06	4.26e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PSMD6—type 2 diabetes mellitus	7.97e-06	4.26e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SREBF1—type 2 diabetes mellitus	7.97e-06	4.26e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CTGF—type 2 diabetes mellitus	7.82e-06	4.18e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HMGCR—type 2 diabetes mellitus	7.75e-06	4.15e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	7.64e-06	4.09e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ADRA2A—type 2 diabetes mellitus	7.58e-06	4.06e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP2E1—type 2 diabetes mellitus	7.28e-06	3.9e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1A2—type 2 diabetes mellitus	7.2e-06	3.85e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC2A1—type 2 diabetes mellitus	7.2e-06	3.85e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP3A4—type 2 diabetes mellitus	7.02e-06	3.76e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	6.99e-06	3.74e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—type 2 diabetes mellitus	6.98e-06	3.73e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GCG—type 2 diabetes mellitus	6.91e-06	3.69e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC2A4—type 2 diabetes mellitus	6.91e-06	3.69e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.44e-06	3.44e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—type 2 diabetes mellitus	6.42e-06	3.44e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—type 2 diabetes mellitus	6.42e-06	3.44e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	5.95e-06	3.18e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.95e-06	3.18e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	5.93e-06	3.17e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.92e-06	3.17e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.92e-06	3.17e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	5.85e-06	3.13e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	5.68e-06	3.04e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	5.52e-06	2.95e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	5.42e-06	2.9e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	5.31e-06	2.84e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	5.29e-06	2.83e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	5.15e-06	2.75e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	5.08e-06	2.72e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	4.88e-06	2.61e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	4.79e-06	2.56e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	4.64e-06	2.48e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	4.56e-06	2.44e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	4.54e-06	2.43e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	4.49e-06	2.4e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	3.96e-06	2.12e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	3.88e-06	2.08e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	3.56e-06	1.9e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	3.4e-06	1.82e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	3.4e-06	1.82e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	3.11e-06	1.67e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	1.56e-06	8.37e-06	CbGpPWpGaD
